OBJECTIVE: To investigate individual pretreatment serum human chorionic gonadotropin ( @entity3566 ) cutoff value for medical treatment success with single-dose and multi-dose regimen of @entity1499 in tubal ectopic pregnancy. METHODS: Eighty-five @entity1 who received @entity1499 for the treatment of tubal ectopic pregnancy during 2003 to 2015 were selected. Fifty-three @entity1 received a single-dose regimen and 32 @entity1 received a multi-dose regimen. Medical treatment failure was defined as necessity of surgical treatment. The medical treatment success rate was estimated in both regimens and the pretreatment serum @entity3566 titer to predict the success was assessed by receiver operating characteristics curve analysis. RESULTS: Pretreatment clinical and laboratory parameters were similar between group of single-dose regimen and multi-dose regimen. Treatment success rate was 64.2% in the single-dose regimen group and 71.9% in the multi-dose regimen group (P>0.05). Pretreatment serum @entity3566 titer was an independent prognostic factor for treatment success in each regimen. Serum @entity3566 cutoff value to predict the treatment success was 3,026 IU/L in single-dose regimen group and 3,711 IU/L in multi-dose regimen group. CONCLUSION: We recommend use of single-dose regimen when pretreatment serum @entity4398 ,026 IU/L but multi-dose regimen may be favored when initial serum @entity3566 level between 3,026 and 3,711 IU/L.

Pretreatment serum human chorionic gonadotropin cutoff value for medical treatment success with single-dose and multi-dose regimen of XXXX in tubal ectopic pregnancy.

@entity1 :: ('9606', 'Species') :: ['women'] @entity4398 :: ('414061', 'Gene') :: ['hCG <3'] @entity3566 :: ('3342', 'Gene') :: ['hCG'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']
